Scientists’ findings point to novel ways of fighting the mind-robbing disease – if researchers can unravel how a single copy of a very rare gene variant offers at least a little protection.
Alzheimer’s disease
Posted inHealth, Nation & World, News
Alzheimer’s drug that can slow disease gets backing from FDA advisers
If it wins final approval, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. that’s been shown to convincingly slow cognitive decline and memory problems due to Alzheimer’s.
advertisement
Posted inHealth, Nation & World
A gene long thought to just raise the risk for Alzheimer’s may cause some cases
Scientists say the research makes it critical to develop treatments that target the APOE4 gene.
Posted inNews, Politics
Shadowing Trump’s attacks on mental fitness – his own father’s dementia
Donald Trump’s father’s condition also drove a wedge into his family, which fell into years of lawsuits that alleged in part that Donald Trump sought to take advantage of his father’s dementia to wrest control of the family estate.
Posted inHealth, Nation & World, News
Air pollution tied to signs of Alzheimer’s in brain tissue, study finds
A study published this week says the association holds for people who are not already genetically predisposed to Alzheimer’s.
Posted inHealth, Local & State
Portland man takes part in drug trial giving new hope in fight against Alzheimer’s disease
Ralph Carmona participated in a clinical research trial for Leqembi, a new Alzheimer’s drug that he believes stopped his symptoms from progressing.
Posted inTimes Record
Midcoast Walk to End Alzheimer’s returns to Brunswick on Saturday
The fundraising walks kicks off with the Promise Garden Ceremony at 10 a.m. Saturday, Sept. 30.
Posted inOp-eds, Opinion
Insight: Memory, my mother and me
As Mom is less and less herself, I’m trying to come to terms with the person she’s becoming.
Posted inOp-eds, Opinion
Commentary: Who bears the responsibility for decisions about Alzheimer’s treatment?
We’ve been rethinking our approach to the disease with varying degrees of success. Too many questions remain unanswered.
Posted inOp-eds, Opinion
Commentary: Alzheimer’s drug Leqembi gets full FDA nod, but hurdles remain
The rollout is likely to take longer than patients and their families would like.